What Happened to Science?

Over on the New York Times Sunday Dialogue, our colleague, friend, and former guest blogger Dr. Robin Weiss has an conversation on Science and Politics.  What happened to science, Dr. Weiss ponders?  But a disturbing trend threatens future public health initiatives. At the heart of successful public policy lies a shared, bipartisan assumption that science is trustworthy. Lately, politicians unashamedly issue proclamations tantamount to declaring, The world is flat. Climate change is a hoax. Vaccines cause autism. Intelligent design should be taught in biology class alongside evolution. The United States has the best health outcomes in the world. In public health, knowledge is truly power. If politicians no longer agree that sound scientific knowledge is valid, our nation’s health will suffer for decades — or centuries — to come. Readers wrote in with a variety of thoughts: it's the almighty dollar that corrupts politicians and blinds them from the truth, scientific research is underfunded, it's those damn Republicans (you can always blame the Republicans), if not them, then the religious extremists.  Science is wrong, and sometimes just evil.  And Dr. Weiss then responded, I'll let you surf over there to read. I think one of the issues that makes it hard to rely completely on science is that such truths are hard to come by.  For every set of numbers, we have a set of anti-numbers, not to mention the science du jour-...
Source: Shrink Rap - Category: Psychiatrists and Psychologists Authors: Source Type: blogs

Related Links:

During the production of this paper, an error appeared in the title. The title should be, “Immune Checkpoint Inhibition Combined With Intracranial Stereotactic Radiation Therapy in Non-Small Cell Lung Cancer: Is There an Increasing Rate of Radionecrosis or Not? In Regards to Schapira et al, Huppeling et al and Colaco et al.”
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Tags: Erratum Source Type: research
Prostate cancer is the leading cause of cancer treatment –related years lived with disability for men worldwide.1 This has driven a disruptive change in management of favorable-risk prostate cancer such that nearly all National Comprehensive Cancer Network (NCCN) very low-risk patients are recommended conservative management rather than radical therapy. 2 Simultaneously, at the other end of the risk spectrum, treatment intensification with more potent systemic therapies has been the subject of recent trials for men with higher-risk disease (eg, NCT02772588).
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
In the above referenced article, portions of the text and table reading “CALGB 80801” should have read “CALGB 80101,” to correctly reflect the referenced Fuchs CS et al. publication and CALGB study. The authors regret the error.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Tags: Erratum Source Type: research
The authors' letter and translational research work support the question posed in the review1,2: Are we at the tipping point for the era of real-time radiation therapy? The research by Dahele and Verbakel adds additional clinical evidence that real-time 3-dimensional image guided radiation therapy (3D IGRT) can be performed on standard-equipped cancer radiation therapy (RT) systems. Indeed, had it been published or known to us before we wrote the review, their clinical translation of markerless spine tracking3 would have been included as a fourth real-time 3D IGRT implementation on standard-equipped systems.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comment Source Type: research
Multiple randomized studies have demonstrated that breast-conserving therapy (partial mastectomy plus whole breast radiation) can yield survival outcomes equivalent to those of mastectomy (1). However, newer population-based data suggest that breast cancer –specific survival and overall survival with breast-conserving therapy may actually be better than those with mastectomy (2-8). How is this possible? How can removal of the breast yield outcomes inferior to those of a therapy that leaves most of the breast intact and where in-breast failures are r eported to occur in approximately 5% to 10% of patients at 10 y...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
In the world of cancer care, Halstedian paradigms for radical surgery have evolved toward organ preservation strategies without compromising the probability of cure. As such, clinicians have increasingly turned their focus toward minimizing the stigmata of treatment, with patient-centered outcomes having greater influence on decision making. Today, patients are typically able to preserve much of their functional anatomy and cosmesis. For example, selected patients with head and neck cancers are routinely offered a strategy of larynx preservation with upfront radiation therapy and chemotherapy, reserving a more morbid total...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
A 66-year-old ex-smoker presented with metastatic renal cell cancer with lytic lesions in the left femur, T8, and a 1.5-cm lesion in the right lung. A biopsy from the femur confirmed clear cell renal cell cancer; the lung lesion could not be biopsied safely. The patient underwent a radical nephrectomy (pathologically staged as pT3a). He commenced sunitinib, which was stopped owing to severe hypertension, followed by everolimus, stopped after 8 cycles owing to muscle cramping. Repeat imaging demonstrated resolution of the lung nodule but progression in the left femur, T8, and new disease in the anterior right 10th rib and left humerus.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
Publication date: Available online 12 December 2018Source: Social Science &MedicineAuthor(s): Amelia M. Jamison, Sandra Crouse Quinn, Vicki S. FreimuthAbstractVaccine confidence depends on trust in vaccines as products and trust in the system that produces them. In the US, this system consists of a complex network connecting pharmaceutical companies, government agencies, and the healthcare system. We explore narratives from White and African American adults describing their trust in these institutions, with a focus on influenza vaccine. Our data were collected between 2012 and 2014 as part of a mixed-methods investigat...
Source: Social Science and Medicine - Category: Psychiatry & Psychology Source Type: research
MicroRNA‑506‑3p reverses gefitinib resistance in non‑small cell lung cancer by targeting Yes‑associated protein 1. Mol Med Rep. 2018 Nov 29;: Authors: Zhu J, Tao L, Jin L Abstract Epidermal growth factor receptor‑tyrosine kinase inhibitors, such as gefitinib, have been found to be clinically effective in the treatment of patients with non‑small cell lung cancer (NSCLC). However, the therapeutic effect of gefitinib is often limited by the development of gefitinib resistance. MicroRNAs (miRNAs), a group of small non‑coding RNAs, have been demonstrated to be frequently dysregulated in human ...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells. Mol Med Rep. 2018 Dec 07;: Authors: Jing C, Li H, Du Y, Cao H, Liu S, Wang Z, Ma R, Feng J, Wu J Abstract Mitogen‑activated protein kinase kinase (MEK) small molecule inhibitors have been investigated in preclinical or clinical trials for the treatment of cancer. In the present study the genetic test results of 120 patients with colorectal cancer (CRC) were screened and the mutation rate of MEK1 was identified to be 1.67%. MEK inhibition by U0126 significantly decreased ...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
More News: Allergy & Immunology | Autism | Biology | Blogging | Calcium | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Health | Heart | Hormone Replacement Therapy | Hormones | International Medicine & Public Health | Kidney Stones | Low Fat | Men | Nutrition | Podcasts | Politics | Psychiatrists and Psychologists | Science | Smokers | Study | Urology & Nephrology | Vaccines | Vitamins